PTC Therapeutics PTCT Emflaza — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's emflaza — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's emflaza — revenue?
- PTC Therapeutics (PTCT) reported emflaza — revenue of $21.48M in Q1 2026.
- How has PTC Therapeutics's emflaza — revenue changed year-over-year?
- PTC Therapeutics's emflaza — revenue decreased by 55.1% year-over-year, from $47.79M to $21.48M.
- What is the long-term trend for PTC Therapeutics's emflaza — revenue?
- Over 4 years (2021 to 2025), PTC Therapeutics's emflaza — revenue has grown at a -6.0% compound annual growth rate (CAGR), from $187.2M to $146.36M.
- What does emflaza — revenue mean?
- This metric represents the net revenue generated from the sale of the Emflaza product, excluding any taxes collected from customers that are remitted to governmental authorities. It serves as a primary indicator of the product's market demand and commercial performance within the biopharmaceutical portfolio. Tracking this figure allows investors to assess the underlying top-line growth trajectory of the specific therapeutic asset independent of tax-related fluctuations.